Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Assembly Biosciences, Inc. (NASDAQ: ASMB).

Full DD Report for ASMB

You must become a subscriber to view this report.


Recent News from (NASDAQ: ASMB)

Assembly Biosciences misses by $0.04, beats on revenue
Assembly Biosciences (NASDAQ: ASMB ): Q1 EPS of -$0.80 misses by $0.04 . More news on: Assembly Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 07 2018 16:57
Assembly Biosciences Announces First Quarter 2018 Financial Results
INDIANAPOLIS and SAN FRANCISCO, May 07, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics f...
Source: GlobeNewswire
Date: May, 07 2018 16:05
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Your Daily Pharma Scoop: Reata Provides Update, Assembly Biosciences Data, Bellicum's BPX-501
A nalysis focus: Reata Pharmaceuticals Today we will discuss Reata Pharmaceuticals ( RETA ), which provided an update on the phase 2 portion of the CARDINAL study of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD) due to Alport syndrome. Bardo...
Source: SeekingAlpha
Date: April, 13 2018 08:00
Assembly Bio's lead candidate shows positive action in early-stage HBV studies
Assembly Biosciences (NASDAQ: ASMB ) announces positive results from Phase 1a and 1b studies of lead candidate ABI-H0731, in development for the treatment of chronic hepatitis B virus (HBV) infection. The data were presented at The International Liver Congress in Paris. More news on: Ass...
Source: SeekingAlpha
Date: April, 12 2018 06:58
Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference
Robust antiviral activity observed in HBV patients Generally safe and well tolerated Planning underway for Phase 2a studies beginning summer 2018 Company to host conference call on Thursday, April 12 th at 8am ET / 2pm CEST INDIANAPOLIS and SAN FRANCISCO, April 12, 2018...
Source: GlobeNewswire
Date: April, 12 2018 03:10
Assembly Bio conference call tomorrow to review ABI-H0731 data
Assembly Biosciences (NASDAQ: ASMB ) will host a conference call tomorrow, April 12, at 8:00 am ET to review interim data from Phase 1a and 1b studies of lead candidate ABI-H0731 that are being presented at the International Liver Congress in Paris. More news on: Assembly Biosciences, In...
Source: SeekingAlpha
Date: April, 11 2018 07:06
Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL
INDIANAPOLIS and SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disor...
Source: GlobeNewswire
Date: April, 10 2018 17:39
Report: Developing Opportunities within Assembly Biosciences, Guaranty, Noble Midstream Partners LP, Lithia Motors, Vectrus, and Kforce - Future Expectations, Projections Moving into 2018
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assembly Biosciences, Inc. (NASDAQ:ASMB), Guaranty Bancorp (NASDAQ:GBNK)...
Source: GlobeNewswire
Date: April, 04 2018 08:00
Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome
INDIANAPOLIS and SAN FRANCISCO, April 02, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disor...
Source: GlobeNewswire
Date: April, 02 2018 16:54

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1741.9642.5343.1441.28145,036
2017-06-2021.9821.9322.3521.7960,408
2017-06-1921.9221.8822.447721.6279,348
2017-06-1621.7121.7623.0120.9791,814
2017-06-1522.1721.8322.7921.0584,016

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1736,31858,67161.9011Short
2018-08-1640,32784,74947.5840Short
2018-08-1528,72877,28937.1696Short
2018-08-1432,116110,64529.0262Cover
2018-08-1324,88656,57643.9868Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ASMB.


About Assembly Biosciences, Inc. (NASDAQ: ASMB)

Logo for Assembly Biosciences, Inc. (NASDAQ: ASMB)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $865,264,405 - 05/14/2018
    • Authorized: 50,000,000 - 05/01/2018
    • Issue and Outstanding: 20,547,718 - 05/01/2018

     


    Recent Filings from (NASDAQ: ASMB)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 07 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 07 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 19 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 19 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 12 2018
    Preliminary proxy statement providing notification matters to be brought to a vote
    Filing Type: PRE 14AFiling Source: edgar
    Filing Date: April, 06 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 02 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 12 2018
    Annual report with a comprehensive overview of the company
    Filing Type: 10-KFiling Source: edgar
    Filing Date: March, 08 2018
    Statement of beneficial ownership of common stock by certain persons
    Filing Type: SC 13GFiling Source: edgar
    Filing Date: February, 14 2018

     

     


    Daily Technical Chart for (NASDAQ: ASMB)

    Daily Technical Chart for (NASDAQ: ASMB)


    Stay tuned for daily updates and more on (NASDAQ: ASMB)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ASMB)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ASMB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ASMB and does not buy, sell, or trade any shares of ASMB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/